METCrusaders· @metcrusaders · X·· 9 小时前评分70
正文 · 原文
#ESMO26 | Dr. Rebecca Heist (@MGHThoracicOnc): Is MET testing the next step in personalized lung cancer treatment?
SANOVO showed improved median PFS (24.9 vs 13.8 months) with savolitinib + osimertinib in EGFR-mutated, MET-overexpressing NSCLC. Could MET guide first-line treatment selection?
#METCrusaders #NSCLC #LungCancer #SANOVO #PrecisionMedicine #lcsm
8 浏览 · 0 赞 · 0 转发 · 0 回复
来源：METCrusaders · x.com